Brown Brothers Harriman & Co’s Neurocrine Biosciences NBIX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.04K	Hold	24	–	–	﹤0.01%	1613
2026 Q1	$3.16K	Hold	24	–	–	﹤0.01%	1615
2025 Q4	$3.4K	Buy	+24	New	+$3.48K	﹤0.01%	1612
2024 Q4	–	Sell	-25	Closed	-$2.88K	–	1538
2024 Q3	$2.88K	Buy	+25	New	+$3.43K	﹤0.01%	1250
2023 Q4	–	Sell	-18	Closed	-$2.02K	–	1233
2023 Q3	$2.02K	Hold	18	–	–	﹤0.01%	1104
2023 Q2	$1.7K	Hold	18	–	–	﹤0.01%	1143
2023 Q1	$1.82K	Sell	18 -249	-93%	-$25.9K	﹤0.01%	1162
2022 Q4	$31.9K	Sell	267 -164	-38%	-$19.2K	﹤0.01%	796
2022 Q3	$46K	Buy	431 +182	+73%	+$18.5K	﹤0.01%	758
2022 Q2	$24K	Buy	+249	New	+$23K	﹤0.01%	845
2020 Q2	–	Sell	-6	Closed	-$1K	–	1117
2020 Q1	$1K	Hold	6	–	–	﹤0.01%	1024
2019 Q4	$1K	Sell	6 -4	-40%	-$419	﹤0.01%	1075
2019 Q3	$1K	Hold	10	–	–	﹤0.01%	1140
2019 Q2	$1K	Buy	+10	New	+$821	﹤0.01%	1040
2018 Q3	–	Sell	-25	Closed	-$2K	–	864
2018 Q2	$2K	Hold	25	–	–	﹤0.01%	781
2018 Q1	$2K	Sell	25 -31	-55%	-$2.62K	﹤0.01%	755
2017 Q4	$4K	Buy	+56	New	+$3.82K	﹤0.01%	892
2017 Q1	–	Sell	-92	Closed	-$4K	–	852
2016 Q4	$4K	Hold	92	–	–	﹤0.01%	786
2016 Q3	$5K	Hold	92	–	–	﹤0.01%	686
2016 Q2	$4K	Buy	+92	New	+$4.24K	﹤0.01%	736

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brown Brothers Harriman & Co's NBIX Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 24 shares worth $4.04K. The position accounts for ﹤0.01% of the portfolio, ranked #1613.

Brown Brothers Harriman & Co first reported a position in NBIX in Q2 2016 and has held it in 20 quarters since. The position peaked at $46K in Q3 2022. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Brown Brothers Harriman & Co held 24 shares of Neurocrine Biosciences worth $4.04K as of Q2 2026.
Brown Brothers Harriman & Co left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1613 holding.
Brown Brothers Harriman & Co first reported a position in Neurocrine Biosciences in Q2 2016 and has held it in 20 quarters since.
Brown Brothers Harriman & Co's Neurocrine Biosciences position peaked at $46K in Q3 2022.
775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.